Virpax Pharmaceuticals Has Formed A New Wholly-owned Subsidiary, Novvae Pharmaceuticals, Which Has Been Established To Focus Exclusively On Advancing Virpax's OTC Pipeline
Portfolio Pulse from Benzinga Newsdesk
Virpax Pharmaceuticals has established a new wholly-owned subsidiary, Novvae Pharmaceuticals, to focus exclusively on advancing Virpax's over-the-counter (OTC) pipeline.
September 18, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The formation of Novvae Pharmaceuticals by Virpax could potentially boost Virpax's OTC pipeline, possibly leading to increased revenues and growth for the company.
The formation of a new subsidiary focused on advancing Virpax's OTC pipeline indicates a strategic move to potentially increase the company's revenues and growth. This could positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100